Drug intelligence / Profile preview

epinephrine (Antares Pharma, Inc.)

Development stage: Preclinical
Lead developer: Halozyme
Modality: Small Molecules
Administration: Intramuscular, Subcutaneous

Overview

ATRS-1903 is a rescue pen auto-injector being developed by Halozyme Therapeutics (following its acquisition of Antares Pharma) for the emergency treatment of anaphylaxis. The product utilizes the proprietary Vibex® pressure-assisted auto-injector technology, which is designed to provide rapid and reliable intramuscular delivery of epinephrine. ATRS-1903 is intended to offer a competitive alternative in the epinephrine auto-injector market, potentially improving upon the ease of use and reliability of existing emergency allergy treatments. The program was in preclinical development at the time of the Halozyme acquisition and remains part of the combined company's specialty product pipeline.

Other names: epinephrine auto-injector

Targets

ADRA1A (α1A)ADRA2A (α2A)ADRB2 (β2)ADRB1 (β1)

Beyond the preview

Go deeper on epinephrine (Antares Pharma, Inc.).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on epinephrine (Antares Pharma, Inc.).

Explore the full profile